Arrowstreet Capital
VYGR icon

Arrowstreet Capital’s Voyager Therapeutics VYGR Stock Holding History

Arrowstreet Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,320
Closed -$189K – 1797
2024
Q1 		$189K Buy
+20,320
New +$172K ﹤0.01% 1587
2023
Q4 		– Sell
-140,020
Closed -$1.08M – 1573
2023
Q3 		$1.08M Sell
140,020
-20,457
-13% -$187K ﹤0.01% 973
2023
Q2 		$1.84M Buy
+160,477
New +$1.66M ﹤0.01% 843
2020
Q1 		– Sell
-48,900
Closed -$682K – 2140
2019
Q4 		$682K Buy
+48,900
New +$711K ﹤0.01% 1426

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Arrowstreet Capital's VYGR Position: Q2 2024 in Review

Arrowstreet Capital sold out of Voyager Therapeutics (VYGR) in Q2 2024, closing a stake of 20,320 shares — an estimated $189K sold.

Arrowstreet Capital first reported a position in VYGR in Q4 2019 and held it in 4 quarters. The position peaked at $1.84M in Q2 2023. 127 funds tracked by Wall St. Rank hold VYGR as of Q2 2024.

  • Arrowstreet Capital reported no remaining Voyager Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Arrowstreet Capital sold 20,320 Voyager Therapeutics shares in Q2 2024, an estimated $189K.
  • Arrowstreet Capital first reported a position in Voyager Therapeutics in Q4 2019 and held it in 4 quarters.
  • Arrowstreet Capital's Voyager Therapeutics position peaked at $1.84M in Q2 2023.
  • 127 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2024.

Based on Arrowstreet Capital's 13F filing for Q2 2024, filed 14 Aug 2024.